New research published in BMC Microbiology reveals that Pseudomonas aeruginosa and Acinetobacter baumannii are increasingly resistant to last-line carbapenem antibiotics in hospital settings. A study of 59 clinical isolates from a tertiary care hospital in central Nepal found that 76.3% of these pathogens are multidrug-resistant, with 62.7% showing carbapenem resistance, according to researchers Syangtan, Khanal, and Bista.
Drivers of Multidrug Resistance in Clinical Isolates
The prevalence of antibiotic resistance in hospital environments is fueled by the presence of specific genetic markers that allow bacteria to survive standard medical treatments. According to the study, nearly two-thirds of the analyzed isolates produced extended-spectrum beta-lactamases (ESBLs). These enzymes effectively break down common antibiotics, rendering them useless against the infection.
Molecular analysis identified that 70% of carbapenem-resistant isolates carried at least one known resistance gene. Among P. aeruginosa samples, the blaVIM-2 gene was the most common, appearing in 58.3% of resistant cases. For A. baumannii, the blaOXA-23 gene was detected in more than half of the resistant isolates. The study noted that some samples contained “cocktails” of resistance genes, such as blaNDM-1 and blaOXA-58, which significantly narrow the options for effective patient care.
Did you know?
The World Health Organization classifies P. aeruginosa and A. baumannii as priority bacterial pathogens. Their ability to cause healthcare-associated infections combined with their growing resistance makes them a top concern for global health authorities.
Clinical Impact and Infection Control
Patients infected with these resistant strains face higher risks of complications. The presence of these pathogens is linked to longer hospital stays and increased healthcare costs, as standard treatments fail to clear the infection. The study authors emphasize that these resistance mechanisms complicate the management of critically ill patients who are already vulnerable to secondary infections.
To combat this, the researchers suggest that routine antimicrobial resistance surveillance must become a standard practice. By identifying specific resistance genes, hospitals can better monitor the spread of dangerous strains. This data is vital for informing antibiotic stewardship programs, which aim to optimize how antibiotics are prescribed to prevent further resistance from developing.
Pro Tip: The Role of Molecular Monitoring
While traditional susceptibility testing identifies which drugs fail, molecular characterization—identifying the specific genes like blaCTX-M or blaTEM—allows hospitals to track the evolution of resistance patterns in real-time, providing a proactive rather than reactive approach to infection control.
Future Trends in Antimicrobial Resistance
As Syangtan et al. conclude, active monitoring is not just a research task; it is a critical component of infection control that directly impacts patient outcomes as antimicrobial resistance continues to evolve.
Frequently Asked Questions
- What are carbapenem-resistant organisms?
These are bacteria that have developed the ability to survive treatment with carbapenems, a class of antibiotics often reserved for severe or high-risk infections. - Why is Acinetobacter baumannii a priority pathogen?
The WHO identifies it as a priority because it frequently causes healthcare-associated infections and shows high levels of resistance to multiple drug classes, making it difficult to treat in clinical settings. - What are metallo-beta-lactamases?
These are enzymes produced by certain bacteria that can inactivate carbapenem antibiotics, effectively making the bacteria resistant to these drugs.
Are you a healthcare professional or researcher interested in infection control? Subscribe to our newsletter for the latest updates on antimicrobial resistance and hospital safety protocols.
Worth a look
